Verrica Pharmaceuticals Inc. Proceeds from Sale and Maturity of Marketable Securities
Verrica Pharmaceuticals Inc. (VRCA) reported Proceeds from Sale and Maturity of Marketable Securities of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-29.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities · last filed 2024-02-29
- Verrica Pharmaceuticals Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2023-12-31 was $0.00, a 100.00% decline year-over-year.
- Verrica Pharmaceuticals Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2023-09-30 was $0.00, a 100.00% decline year-over-year.
- Verrica Pharmaceuticals Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2023-06-30 was $0.00, a 100.00% decline year-over-year.
- Verrica Pharmaceuticals Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2023-03-31 was $0.00, a 100.00% decline year-over-year.
- Verrica Pharmaceuticals Inc. proceeds from sale and maturity of marketable securities for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- Verrica Pharmaceuticals Inc. proceeds from sale and maturity of marketable securities for fiscal 2022 was $59.01M, a 14.48% decline from fiscal 2021.
- Verrica Pharmaceuticals Inc. proceeds from sale and maturity of marketable securities for fiscal 2021 was $69.00M, a 1.22% decline from fiscal 2020.
- Verrica Pharmaceuticals Inc. proceeds from sale and maturity of marketable securities for fiscal 2020 was $69.85M, a 40.66% decline from fiscal 2019.
| Period end | Proceeds from Sale and Maturity of Marketable Securities 3 month | Proceeds from Sale and Maturity of Marketable Securities 6 month | Proceeds from Sale and Maturity of Marketable Securities 9 month | Proceeds from Sale and Maturity of Marketable Securities 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $0.00 derived: sum of 2 quarters · filed 2024-02-29 | $0.00 derived: sum of 3 quarters · filed 2024-02-29 | $0.00 10-K · filed 2024-02-29 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $0.00 derived: sum of 2 quarters · filed 2023-11-09 | $0.00 10-Q · filed 2023-11-09 | $7.00M derived: sum of 4 quarters · filed 2024-02-29 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $0.00 10-Q · filed 2023-08-08 | $7.00M derived: sum of 3 quarters · filed 2024-02-29 | $9.01M derived: sum of 4 quarters · filed 2024-02-29 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-09 | $7.00M derived: sum of 2 quarters · filed 2024-02-29 | $9.01M derived: sum of 3 quarters · filed 2024-02-29 | $11.50M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-12-31 | $7.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $9.01M derived: sum of 2 quarters · filed 2024-02-29 | $11.50M derived: sum of 3 quarters · filed 2024-02-29 | $59.01M 10-K · filed 2024-02-29 |
| 2022-09-30 | $2.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $4.50M derived: sum of 2 quarters · filed 2023-11-09 | $52.01M 10-Q · filed 2023-11-09 | $66.21M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $2.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $50.00M 10-Q · filed 2023-08-08 | $64.20M derived: sum of 3 quarters · filed 2023-08-08 | $83.40M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $47.51M 10-Q · filed 2023-05-09 | $61.71M derived: sum of 2 quarters · filed 2023-05-09 | $80.91M derived: sum of 3 quarters · filed 2023-05-09 | $96.01M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $14.20M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $33.40M derived: sum of 2 quarters · filed 2023-03-06 | $48.50M derived: sum of 3 quarters · filed 2023-03-06 | $69.00M 10-K · filed 2023-03-06 |
| 2021-09-30 | $19.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $34.30M derived: sum of 2 quarters · filed 2022-11-07 | $54.80M 10-Q · filed 2022-11-07 | $66.90M derived: sum of 4 quarters · filed 2022-11-07 |
| 2021-06-30 | $15.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $35.60M 10-Q · filed 2022-08-11 | $47.70M derived: sum of 3 quarters · filed 2022-08-11 | $61.09M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $20.50M 10-Q · filed 2022-05-09 | $32.60M derived: sum of 2 quarters · filed 2022-05-09 | $45.99M derived: sum of 3 quarters · filed 2022-05-09 | $65.99M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | $12.10M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-02 | $25.49M derived: sum of 2 quarters · filed 2022-03-02 | $45.49M derived: sum of 3 quarters · filed 2022-03-02 | $69.85M 10-K · filed 2022-03-02 |
| 2020-09-30 | $13.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $33.39M derived: sum of 2 quarters · filed 2021-11-12 | $57.75M 10-Q · filed 2021-11-12 | $82.25M derived: sum of 4 quarters · filed 2021-11-12 |
| 2020-06-30 | $20.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $44.35M 10-Q · filed 2021-08-10 | $68.86M derived: sum of 3 quarters · filed 2021-08-10 | $91.50M derived: sum of 4 quarters · filed 2021-08-10 |
| 2020-03-31 | $24.36M 10-Q · filed 2021-05-07 | $48.85M derived: sum of 2 quarters · filed 2021-05-07 | $71.50M derived: sum of 3 quarters · filed 2021-05-07 | $99.70M derived: sum of 4 quarters · filed 2021-05-07 |
| 2019-12-31 | $24.50M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-17 | $47.15M derived: sum of 2 quarters · filed 2021-03-17 | $75.35M derived: sum of 3 quarters · filed 2021-03-17 | $117.72M 10-K · filed 2021-03-17 |
| 2019-09-30 | $22.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $50.85M derived: sum of 2 quarters · filed 2020-11-09 | $93.22M 10-Q · filed 2020-11-09 | |
| 2019-06-30 | $28.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $70.56M 10-Q · filed 2020-08-05 | ||
| 2019-03-31 | $42.37M 10-Q · filed 2020-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |